An interventional study of 3D Therapy Thrive in Opioid Use Disorder, sponsored by 3D Therapy, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.
Sponsored by 3D Therapy, LLC · Not applicable, Interventional, and Device feasibility
This study aims to evaluate feasibility of a virtual reality software device and measure the effects of the intervention on OUD patient mood, tension and cravings, as well as the effect of treatment on patient retention to their inpatient detox protocol.
The primary objective of this study is to evaluate the feasibility and preliminary effectiveness of a novel virtual reality (VR) based intervention; 3D Therapy Thrive (3DTT). Inpatient detoxification can improve outcomes for individuals with opioid use disorder (OUD), however patients often leave treatment early due to mood, tension, and cravings associated with opioid withdrawal. Subjects were recruited from a community inpatient detoxification program and received up to two sessions of 3DTT. The patients completed surveys to assess their mood, distress, cravings, and overall satisfaction with the experience. Retention was measured by protocol completion as reported by clinic staff, independent of the study. A group of patients with OUD consecutively admitted to the program comprised a comparison treatment-as-usual (TAU) group.
1,411 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
This study's enrollment of 40 is below the median of 63 across 1,123 interventional studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →This is the only study on the registry with 3D Therapy, LLC as lead sponsor.
Counted across the registry records on this site, refreshed daily.
1.18 years or older
Exclusion Criteria
Participants received the active virtual therapy intervention.
Device: 3D Therapy Thrive
A group of patients concurrently on the ATS unit, otherwise eligible to participate in the study who did not enroll, and did not receive an intervention.
A novel virtual reality software intervention that utilizes elements of Cognitive Behavioral Therapy to improve outcomes for inpatients with OUD.
Retention in Treatment
Medical record indicating whether patient completed detox protocol (i.e., completed, left against medical advice, administratively discharged, or moved to higher level of care)
Time frame: At departure from facility, through study completion, an average of 10 days
Feasibility and Tolerability of 3DTT
Feasibility and tolerability of 3DTT was measured by the Side Effects Questionnaire.
Time frame: Immediately after each treatment
Mood
Depressive symptoms as measured by the AB-POMS depression scale (0-4, not at all to extremely)
Time frame: Before and after each treatment, approximately every other day for up to 5 days
Anxiety
Anxiety symptoms as measured by the AB-POMS scale (0-4, not at all to extremely)
Time frame: Before and after each treatment, approximately every other day for up to 5 days
Cravings
Opioid cravings as measured by the Visual Analog Scale (1-10, with higher scores indicating greater cravings.)
Time frame: Before and after each treatment, approximately every other day for up to 5 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.